Education
About Us
Working with TipRanks
Follow Us
Dr. Martens Plc (DE:3U2)
FRANKFURT:3U2
3U2 Stock Chart & Stats
€0.74
-€0.09(-9.68%)
At close: 4:00 PM EST
€0.74
-€0.09(-9.68%)
Day’s Range― - ―
52-Week Range€0.49 - €1.11
Previous CloseN/A
Volume0.00
Average Volume (3M)406.00
Market Cap
€770.21M
Enterprise Value€959.64M
Total Cash (Recent Filing)€95.70M
Total Debt (Recent Filing)€397.10M
Price to Earnings (P/E)40.5
Beta1.00
Next Earnings
May 28, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding967,319,600
10 Day Avg. Volume2
30 Day Avg. Volume406
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.34
Price to Sales (P/S)0.62
P/FCF Ratio2.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.07Price Target Upside45.01% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA near-65% gross margin reflects persistent pricing power and a premium brand that supports product-level profitability. This margin buffer helps absorb cost inflation and supports reinvestment in DTC, wholesale balance, and product development over the medium term.
Strong Free Cash FlowConsistent free cash flow growth funds operations, debt reduction, and strategic investments without reliance on external capital. Good cash conversion despite lower net income increases financial flexibility and supports sustained investment in stores, e‑commerce, and product ranges.
Reduced Net Debt / Manageable LeverageMaterial year-on-year net debt reduction and a net bank debt position provide more headroom. Lower leverage (net debt-to-EBITDA ~2.1x) improves resilience to demand cycles, reduces interest strain, and increases capacity for capex, marketing and selective expansion.
Bears Say
Declining RevenueNegative revenue growth indicates weakening top-line momentum that can erode scale advantages in sourcing and retail. Sustained declines constrain operating leverage, limit funding for brand initiatives, and increase reliance on margin improvements or cost cuts to restore profitability.
Collapse In ROEA dramatic fall in ROE signals deteriorating returns on invested capital and weaker shareholder value generation. This sharp decline suggests operational inefficiencies or pricing pressure that, if persistent, undermine long‑term capital allocation and investor confidence.
Very Low Net MarginA sub-1% net margin leaves the business highly exposed to cost shocks, tariffs, and regional weakness. Even with strong gross margins, slim bottom-line profitability limits reinvestment capacity, makes dividend continuity harder, and raises the bar for sustained recovery.
Dr. Martens Plc News
3U2 FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
Dr. Martens Plc lowest stock price was €0.49 and its highest was €1.11 in the past 12 months.
What is Dr. Martens Plc’s market cap?
Dr. Martens Plc’s market cap is €770.21M.
When is Dr. Martens Plc’s upcoming earnings report date?
Dr. Martens Plc’s upcoming earnings report date is May 28, 2026 which is in 96 days.
How were Dr. Martens Plc’s earnings last quarter?
Dr. Martens Plc released its earnings results on Nov 20, 2025. The company reported -€0.01 earnings per share for the quarter, the consensus estimate of -€0.01 by €0.
Is Dr. Martens Plc overvalued?
According to Wall Street analysts Dr. Martens Plc’s price is currently Undervalued.
Does Dr. Martens Plc pay dividends?
Dr. Martens Plc does not currently pay dividends.
What is Dr. Martens Plc’s EPS estimate?
Dr. Martens Plc’s EPS estimate is 0.05.
How many shares outstanding does Dr. Martens Plc have?
Dr. Martens Plc has 967,319,600 shares outstanding.
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Dr. Martens Plc reported an EPS of -€0.01 in its last earnings report, expectations of -€0.01. Following the earnings report the stock price went up 0.556%.
Which hedge fund is a major shareholder of Dr. Martens Plc?
Currently, no hedge funds are holding shares in DE:3U2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Martens Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€1.07 (45.01% Upside)
€1.07 (45.01% Upside)
Insider Transactions
Bought Shares
Worth £155.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.87%
12-Months-Change
Fundamentals
Return on Equity
1.23%
Trailing 12-Months
Asset Growth
-6.57%
Trailing 12-Months
Company Description
Dr. Martens Plc
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
3U2 Stock 12 Month Forecast
Average Price Target
€1.07
▲(45.01% Upside)
Technical Analysis
Options Prices
Currently, No data available
---